Gambling
Drug research and approvals for gambling: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 18 studies of gambling are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 18
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 18 recruiting on ClinicalTrials.gov ↗- Digital Cognitive Behavioral Therapy for Gambling DisorderNCT07863440 · Not applicable · Universitas Indonesia · starts Nov 1, 2026
- Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot StudyNCT07391332 · Phase 2 · Nantes University Hospital · starts Oct 8, 2026
- Is Craving a Central Criterion for Diagnosing a Behavioral Addiction?NCT07854912 · Not reported · University of Bordeaux · starts Sep 2, 2026
- Effect of High-Intensity Transcranial Alternating Current Stimulation on Gambling Disorder: A Randomized Controlled…NCT07228182 · Not applicable · Shanghai Mental Health Center · starts Jun 1, 2026
- Effects of Proactive Call to Customers of Norsk Rikstoto (Horse Gambling Operator in Norway): A Randomized Controlled…NCT07028450 · Not applicable · University of Bergen · starts Feb 16, 2026
- Interaction Between Atypical Work Schedules and/or Idel Time at Work on At-risk Gambling PracticesNCT07421765 · Not reported · Centre Hospitalier Universitaire de Nīmes · starts Feb 5, 2026
- Change 4 Better (C4B)NCT06963931 · Not applicable · Yale University · starts May 1, 2025
- Evaluation of the Gambling Habits of Adolescents and Young Adults Post-COVID-19 and Implementation of a Digital Escape…NCT06904794 · Not applicable · Hospital Miguel Servet · starts Apr 2, 2025
- Internet-based Versus Synchronous Cognitive Behavioural Therapy for Patients With Gambling DisorderNCT06989125 · Not applicable · Aarhus University Hospital · starts Feb 24, 2025
- Mindfulness as an add-on Intervention in Treatment for Problem Gambling in Clinical Settings in SwedenNCT06561139 · Not applicable · Region Skane · starts Aug 15, 2024
Drug Pipeline
3 in phase 3, 6 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Naltrexone
- Phase 3 Opioid receptors; mu/kappa/delta antagonist
- Topiramate
- Phase 3 Carbonic anhydrase II inhibitor
- Olanzapine
- Phase 3 Serotonin 2a (5-HT2a) receptor antagonist
- Naloxone
- Phase 2 Opioid receptors; mu/kappa/delta antagonist
- Tolcapone
- Phase 2 Catechol O-methyltransferase inhibitor
- Memantine
- Phase 2 Glutamate [NMDA] receptor negative allosteric modulator
- Ecopipam
- Phase 2 Dopamine D1 receptor antagonist
- Nalmefene
- Phase 2 Mu opioid receptor antagonist
- Milk thistle
- Phase 2
- Acetylcysteine
- Phase 1 Glutathione precursor
How Its Trials Ended
131 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 48% met their primary endpoint, 17% missed it and 35% stopped early.
- Completed, result not reported5441%
- Ongoing2922%
- Status unknown2519%
- Met its primary endpoint118%
- Stopped: other or unclear54%
- Missed its primary endpoint43%
- Stopped: enrollment or feasibility32%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA